Loading stock data…
$22.09-2.06 (-8.53%)
Alto Neuroscience, Inc.
ANRO in the Healthcare sector is trading at $22.09 with a market capitalization of $942M. Wall Street consensus targets $38.38 (10 analysts), implying a +73.8% move over the next 12 months. The stock is currently 41% below its 52-week high of $37.48, remaining 7.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.13M↓ | -$27.14M↓ | -$17.05M↓ | -$14.95M↑ | -$18.68M |
| Net Income | -$27.64M↓ | -$26.24M↓ | -$16.18M↓ | -$14.18M↑ | -$17.71M |
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It...